Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era

Allogeneic hematopoietic cell transplantation (allo HCT) remains a valuable alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on allo HCT outcomes in the era of new HL therapies are needed. We evaluated 72 R/R HL patients who received reduced intensity conditioning (RIC) allo HCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Hegerova, Livia, Cao, Qing, Lazaryan, Aleksander, McClune, Brian L., Weisdorf, Daniel J., Brunstein, Claudio G., Bachanova, Veronika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415418/
https://www.ncbi.nlm.nih.gov/pubmed/28134921
http://dx.doi.org/10.1038/bmt.2016.357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415418/
https://www.ncbi.nlm.nih.gov/pubmed/28134921
http://dx.doi.org/10.1038/bmt.2016.357

Ejemplares similares